American HealthCare Capital is pleased to introduce a 3.0 Specialty Pharmacy URAC accredited and 340b pharmacy providing Specialty, Retail, and Compounding medications to patients with licenses in four states (GA, NC, SC, VA). The pharmacy has been in business since 2013 and has been growing steadily over the past three years. Their medication therapies have been focused on Oncology, Rheumatology, Dermatology, Cardiology, and Orthopedics. They are currently securing distribution for medications focused on Fatty Liver disease, a drug therapy expected to have a market cap of $35 Billion within the next decade.
The company’s payer mix is 71% Private Insurance, 17% Cash Payments, 5% Medicare, 2.44% Medicaid, and 4.56% Other. Gross revenues have shown steady growth over the years and are currently on track to reach $36 Million in 2017, with an adjusted EBITDA of $3.15 Million. They fill an average of 800 scrips per week. The majority of their revenues are derived from manufacturer direct contracts with steady growth in oncology. They are heavily sought after by specialty pharmacy manufacturers.
The current owners are selling their interest to focus on other business ventures, but are willing to stay involved to ensure a smooth transition. The entire staff, including an experienced Specialty Pharmacist is expected to stay on with the new ownership.
The asking price for this opportunity is $21 Million plus inventory.
If you would like to learn more, please contact us for a Confidentiality Agreement that will allow us to share more detailed information with you.